ONCOLOGY Nurse Edition February 2009, Vol 23 No 2

Sessions of interest at the 2025 Gastrointestinal Cancers Symposium will include data on colorectal cancer, pancreatic ductal adenocarcinoma, and more.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Dostarlimab/chemotherapy elicited a 31% decrease in the risk of death compared with placebo/chemotherapy in locally advanced/recurrent endometrial cancer.

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.